Michael Demurjian
Vorstandsvorsitzender bei Aspargo Laboratories, Inc.
Aktive Positionen von Michael Demurjian
Unternehmen | Position | Beginn | Ende |
---|---|---|---|
Tyme, Inc.
Tyme, Inc. BiotechnologyHealth Technology Part of Syros Pharmaceuticals, Inc., Tyme, Inc. is a company that provides research and development services focused on developing drug candidates for the treatment of cancer. The company is based in Wilmington, DE. Steve Hoffman has been the CEO of the company since 2013. Tyme was acquired by Tyme Technologies, Inc., part of Syros Pharmaceuticals, Inc. from September 19, 2022 on March 05, 2015. | Geschäftsführer | - | - |
Aspargo Laboratories, Inc.
Aspargo Laboratories, Inc. Pharmaceuticals: MajorHealth Technology Aspargo Laboratories, Inc. is a clinical stage pharmaceutical company, which focuses on developing an oral spray formulation of sildenafil. Its products include Sildenafil Oral Spray, an oral liquid suspension of sildenafil citrate administered via a spray pump that dispenses 12.5 mg of sildenafil per push of the pump or via an individual single liquid unit dispensing 100 mg per unit. The company was founded in 2019 and is headquartered in Englewood Cliffs, NJ. | Vorstandsvorsitzender | - | - |
Vorsitzender | - | - |
Karriereverlauf von Michael Demurjian
Ehemalige bekannte Positionen von Michael Demurjian
Unternehmen | Position | Beginn | Ende |
---|---|---|---|
TYME TECHNOLOGIES, INC. | Direktor/Vorstandsmitglied | 01.04.2015 | 15.03.2019 |
Geschäftsführer | 01.04.2015 | 15.03.2019 | |
Finanzdirektor/CFO | 01.04.2015 | 15.05.2015 | |
Gründer | 22.11.2011 | 15.03.2019 | |
Mikronite Technologies Group, Inc.
Mikronite Technologies Group, Inc. Auto Parts: OEMProducer Manufacturing Mikronite Technologies Group, Inc. provides material surfacing technologies. The company was founded by Michael Demurjian and Steve Hoffman and is headquartered in Eatontown, NJ. | Gründer | 01.01.1993 | 01.01.2007 |
Vertrieb & Marketing | 01.01.1993 | 01.01.2007 | |
Luminant Biosciences LLC | Gründer | 01.09.2011 | - |
Corporate Officer/Principal | 01.09.2011 | - |
Ausbildung von Michael Demurjian
New York University | Undergraduate Degree |
Statistik
International
Vereinigte Staaten | 7 |
Operativ
Founder | 3 |
Chief Operating Officer | 2 |
Director/Board Member | 1 |
Sektoral
Health Technology | 4 |
Consumer Services | 2 |
Producer Manufacturing | 2 |
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Unternehmensverbindungen
Private Unternehmen | 5 |
---|---|
Tyme Technologies, Inc.
Tyme Technologies, Inc. Pharmaceuticals: MajorHealth Technology Tyme Technologies, Inc. operates as a biotechnology company, which engages in the development and commercialization of cancer therapies. It offers a clinical program named SM-88 which is a novel, oral, and monotherapy investigational agent that aims to disrupt the cancer cell's protein synthesis. The company was founded by Steve Hoffman and Michael Demurjian on November 22, 2011 and is headquartered in Bedminster, NJ. | Health Technology |
Tyme, Inc.
Tyme, Inc. BiotechnologyHealth Technology Part of Syros Pharmaceuticals, Inc., Tyme, Inc. is a company that provides research and development services focused on developing drug candidates for the treatment of cancer. The company is based in Wilmington, DE. Steve Hoffman has been the CEO of the company since 2013. Tyme was acquired by Tyme Technologies, Inc., part of Syros Pharmaceuticals, Inc. from September 19, 2022 on March 05, 2015. | Health Technology |
Mikronite Technologies Group, Inc.
Mikronite Technologies Group, Inc. Auto Parts: OEMProducer Manufacturing Mikronite Technologies Group, Inc. provides material surfacing technologies. The company was founded by Michael Demurjian and Steve Hoffman and is headquartered in Eatontown, NJ. | Producer Manufacturing |
Luminant Biosciences LLC | |
Aspargo Laboratories, Inc.
Aspargo Laboratories, Inc. Pharmaceuticals: MajorHealth Technology Aspargo Laboratories, Inc. is a clinical stage pharmaceutical company, which focuses on developing an oral spray formulation of sildenafil. Its products include Sildenafil Oral Spray, an oral liquid suspension of sildenafil citrate administered via a spray pump that dispenses 12.5 mg of sildenafil per push of the pump or via an individual single liquid unit dispensing 100 mg per unit. The company was founded in 2019 and is headquartered in Englewood Cliffs, NJ. | Health Technology |
- Börse
- Insiders
- Michael Demurjian
- Erfahrung